DK2978419T3 - Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf - Google Patents
Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK2978419T3 DK2978419T3 DK14775675.3T DK14775675T DK2978419T3 DK 2978419 T3 DK2978419 T3 DK 2978419T3 DK 14775675 T DK14775675 T DK 14775675T DK 2978419 T3 DK2978419 T3 DK 2978419T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- compositions
- cell efficiency
- improving cell
- improving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361804690P | 2013-03-24 | 2013-03-24 | |
| US14/140,083 US9872865B2 (en) | 2013-03-24 | 2013-12-24 | Compositions for improving cell viability and methods of use thereof |
| PCT/US2014/018040 WO2014158547A1 (en) | 2013-03-24 | 2014-02-24 | Compositions for improving cell viability and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2978419T3 true DK2978419T3 (da) | 2020-05-04 |
Family
ID=51569584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14775675.3T DK2978419T3 (da) | 2013-03-24 | 2014-02-24 | Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US9872865B2 (da) |
| EP (3) | EP3750531B1 (da) |
| JP (6) | JP6495237B2 (da) |
| KR (6) | KR102607635B1 (da) |
| CN (3) | CN110787169B (da) |
| AU (5) | AU2014242123B2 (da) |
| CA (1) | CA2908683A1 (da) |
| CY (1) | CY1123092T1 (da) |
| DK (1) | DK2978419T3 (da) |
| ES (1) | ES2796250T3 (da) |
| HR (1) | HRP20200990T1 (da) |
| HU (1) | HUE051105T2 (da) |
| LT (1) | LT2978419T (da) |
| ME (1) | ME03747B (da) |
| PL (1) | PL2978419T3 (da) |
| PT (1) | PT2978419T (da) |
| RS (1) | RS60596B1 (da) |
| SI (1) | SI2978419T1 (da) |
| SM (1) | SMT202000326T1 (da) |
| WO (1) | WO2014158547A1 (da) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| DK3307262T3 (da) * | 2015-06-15 | 2021-08-09 | Nmd Pharma As | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser |
| KR101743960B1 (ko) * | 2015-07-06 | 2017-06-08 | 서울대학교산학협력단 | G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물 |
| CA2997947A1 (en) * | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| CA3036511A1 (en) * | 2016-09-12 | 2018-03-15 | Steven Hoffman | Compositions for treating dementia |
| WO2018157014A1 (en) * | 2017-02-24 | 2018-08-30 | Duke University | Metabolic biomarkers for the identification and characterization of alzheimer's disease |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CA3123378A1 (en) * | 2018-12-18 | 2020-06-25 | Santen Pharmaceutical Co., Ltd. | Agent containing 4-phenylbutyrate, for preventing or treating presbyopia |
| EP3968785A4 (en) | 2019-05-14 | 2023-01-11 | Tyme, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| MX2022007276A (es) | 2019-12-16 | 2023-04-25 | Amylyx Pharmaceuticals Inc | Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas. |
| CA3167214A1 (en) * | 2020-02-13 | 2021-08-19 | Michal Geva | Combination therapy for treating amyotrophic lateral using pridopidine and another active agent |
| US10905698B1 (en) * | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| WO2022188029A1 (zh) * | 2021-03-09 | 2022-09-15 | 兆科药业（广州）有限公司 | 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物 |
| WO2022191296A1 (ja) * | 2021-03-10 | 2022-09-15 | 昭和電工マテリアルズ株式会社 | 培地組成物、細胞培養物の製造方法、及び細胞懸濁物 |
| CN113332267A (zh) * | 2021-03-31 | 2021-09-03 | 中山大学孙逸仙纪念医院 | 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用 |
| CN113349300A (zh) * | 2021-06-07 | 2021-09-07 | 湖南农业大学 | 4-苯基丁酸在制备猪肠道保健产品中的应用 |
| EP4429670A1 (en) * | 2021-11-08 | 2024-09-18 | Amylyx Pharmaceuticals Inc. | Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases |
| CN116159068A (zh) * | 2021-11-25 | 2023-05-26 | 香港理工大学深圳研究院 | 胆汁酸和/或胆汁酸受体激动剂的新应用 |
| JP2024542727A (ja) * | 2021-12-02 | 2024-11-15 | マーベルバイオーム・インコーポレイテッド | 迷走神経関連疾患、障害、及び状態を治療するための方法、及び微生物叢組成物、成分、または代謝産物の使用 |
| US20230277630A1 (en) | 2022-03-02 | 2023-09-07 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| US12138272B2 (en) | 2022-05-12 | 2024-11-12 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| US20230372263A1 (en) | 2022-05-17 | 2023-11-23 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| WO2024015281A1 (en) * | 2022-07-11 | 2024-01-18 | AI Therapeutics, Inc. | Apilimod combination therapy |
| WO2024015286A1 (en) * | 2022-07-11 | 2024-01-18 | AI Therapeutics, Inc. | Apilimod combination therapy |
| US20240100069A1 (en) | 2022-09-07 | 2024-03-28 | Amylyx Pharmaceuticals, Inc. | Methods and Compositions for Treating Amyotrophic Lateral Sclerosis |
| US20240139211A1 (en) | 2022-09-29 | 2024-05-02 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| TW202440100A (zh) | 2022-10-31 | 2024-10-16 | 瑞士商諾華公司 | 用於治療由csf-1r調節的疾病的給藥方案 |
| WO2024105168A1 (en) | 2022-11-18 | 2024-05-23 | Inflectis Bioscience | Novel combinations useful for the treatments of als |
| EP4649317A2 (en) * | 2023-01-12 | 2025-11-19 | Population Bio, Inc. | Methods and compositions for screening and treating alzheimer's disease |
| WO2025054193A2 (en) * | 2023-09-05 | 2025-03-13 | Amylyx Pharmaceuticals, Inc. | Compositions and methods for treating subjects with renal impairment |
| CN121197183A (zh) * | 2025-12-01 | 2025-12-26 | 中国农业科学院饲料研究所 | 3-oxoLCA在降低妊娠母体及其子代的氧化应激和炎症中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| CN1770975A (zh) | 2003-04-02 | 2006-05-10 | 明尼苏达大学评议会 | 提高细胞生存能力的方法 |
| CN101048164B (zh) | 2004-11-01 | 2012-05-09 | 柳署弘 | 降低肌萎缩性侧索硬化中神经变性的组合物 |
| AU2005302452B2 (en) | 2004-11-01 | 2010-12-09 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| WO2006086452A1 (en) | 2005-02-10 | 2006-08-17 | Regents Of The University Of Minnesota | Methods for treating visual disorders |
| EP2001484A4 (en) | 2006-03-22 | 2010-04-21 | Harvard College | METHOD AND COMPOSITIONS FOR TREATING HYPERCHOLESTERINEMIA AND ATHEROSCLEROSIS |
| US7737175B2 (en) | 2007-06-01 | 2010-06-15 | Duke University | Methods and compositions for regulating HDAC4 activity |
| US20090252704A1 (en) * | 2008-01-14 | 2009-10-08 | Green Allan M | Therapies for cognition and learning enhancement |
| ES2332687B1 (es) | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| US9283277B2 (en) | 2008-05-12 | 2016-03-15 | Children's Medical Center Corporation | Methods and compositions for the treatment of obesity |
| WO2010008860A1 (en) | 2008-06-23 | 2010-01-21 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| WO2010086864A1 (en) | 2009-02-02 | 2010-08-05 | Galmed International Ltd. | Methods and compositions for treating alzheimer's disease |
| EP2422787A1 (en) | 2010-08-17 | 2012-02-29 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als) |
| US9632075B2 (en) | 2011-11-01 | 2017-04-25 | Meselex, Inc. | Prevention or attenuation of neuropathic pain by bile acids |
| EP2599477A1 (en) | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-Phenylbutyric acid sustained release formulation |
| US20150072967A1 (en) | 2012-03-20 | 2015-03-12 | Metselex, Inc. | Tauroursodeoxycholic acid attentuates or abolishes formation and deposition of amyloid-b peptide |
| US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| SMT201800533T1 (it) | 2013-07-01 | 2018-11-09 | Bruschettini Srl | Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi |
| US10142799B2 (en) | 2014-08-19 | 2018-11-27 | Qualcomm Incorporated | Multicasting traffic using multi-connectivity |
-
2013
- 2013-12-24 US US14/140,083 patent/US9872865B2/en active Active
-
2014
- 2014-02-24 EP EP20169399.1A patent/EP3750531B1/en active Active
- 2014-02-24 KR KR1020227037260A patent/KR102607635B1/ko active Active
- 2014-02-24 EP EP14775675.3A patent/EP2978419B1/en active Active
- 2014-02-24 ES ES14775675T patent/ES2796250T3/es active Active
- 2014-02-24 HU HUE14775675A patent/HUE051105T2/hu unknown
- 2014-02-24 KR KR1020237040555A patent/KR102804813B1/ko active Active
- 2014-02-24 KR KR1020157030684A patent/KR102223250B1/ko active Active
- 2014-02-24 CN CN201911065687.6A patent/CN110787169B/zh active Active
- 2014-02-24 ME MEP-2020-117A patent/ME03747B/me unknown
- 2014-02-24 KR KR1020227015333A patent/KR102460746B1/ko active Active
- 2014-02-24 JP JP2016505464A patent/JP6495237B2/ja active Active
- 2014-02-24 KR KR1020217005747A patent/KR20210025134A/ko not_active Ceased
- 2014-02-24 PT PT147756753T patent/PT2978419T/pt unknown
- 2014-02-24 HR HRP20200990TT patent/HRP20200990T1/hr unknown
- 2014-02-24 LT LTEP14775675.3T patent/LT2978419T/lt unknown
- 2014-02-24 CN CN201480017771.XA patent/CN105050593B/zh active Active
- 2014-02-24 PL PL14775675T patent/PL2978419T3/pl unknown
- 2014-02-24 WO PCT/US2014/018040 patent/WO2014158547A1/en not_active Ceased
- 2014-02-24 RS RS20200676A patent/RS60596B1/sr unknown
- 2014-02-24 SI SI201431557T patent/SI2978419T1/sl unknown
- 2014-02-24 KR KR1020217041070A patent/KR102396714B1/ko active Active
- 2014-02-24 SM SM20200326T patent/SMT202000326T1/it unknown
- 2014-02-24 CA CA2908683A patent/CA2908683A1/en active Pending
- 2014-02-24 DK DK14775675.3T patent/DK2978419T3/da active
- 2014-02-24 CN CN201910114290.5A patent/CN109999043B/zh active Active
- 2014-02-24 AU AU2014242123A patent/AU2014242123B2/en active Active
- 2014-02-24 EP EP24200582.5A patent/EP4509120A3/en active Pending
-
2017
- 2017-12-11 US US15/837,866 patent/US10251896B2/en active Active
-
2019
- 2019-01-31 AU AU2019200658A patent/AU2019200658B2/en active Active
- 2019-02-20 US US16/280,861 patent/US11071742B2/en active Active
- 2019-03-06 JP JP2019040563A patent/JP6766198B2/ja active Active
-
2020
- 2020-02-04 US US16/781,239 patent/US10857162B2/en active Active
- 2020-04-02 US US16/838,975 patent/US20200230156A1/en not_active Abandoned
- 2020-06-30 CY CY20201100604T patent/CY1123092T1/el unknown
- 2020-09-16 JP JP2020155505A patent/JP7080944B2/ja active Active
-
2021
- 2021-03-22 AU AU2021201770A patent/AU2021201770B2/en active Active
- 2021-11-02 US US17/516,845 patent/US12186330B2/en active Active
- 2021-12-21 US US17/557,606 patent/US20220110948A1/en not_active Abandoned
-
2022
- 2022-05-25 JP JP2022085433A patent/JP7242945B2/ja active Active
- 2022-08-23 AU AU2022221410A patent/AU2022221410B2/en not_active Expired - Fee Related
-
2023
- 2023-03-08 JP JP2023035423A patent/JP7596421B2/ja active Active
-
2024
- 2024-11-19 US US18/952,187 patent/US20250275985A1/en active Pending
- 2024-11-27 JP JP2024206282A patent/JP7806187B2/ja active Active
-
2025
- 2025-03-11 AU AU2025201758A patent/AU2025201758A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2978419T3 (da) | Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf | |
| DK2991646T3 (da) | Fremgangsmåder og sammensætninger til forøgelse af cd4+-regulatoriske t-celler | |
| DK3527068T3 (da) | Fremgangsmåder og sammensætninger til forøgelse af effektivitet af målrettet genmodifikation under anvendelse af oligonukleotid-medieret genreparation | |
| DK3556869T3 (da) | Sammensætninger og fremgangsmåder til sekventering af polynukleotider | |
| DK3013964T3 (da) | Sammensætninger til indføring af rna i celler | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| DK3421051T3 (da) | Fremgangsmåder til glycokonjugering og sammensætninger | |
| DK2971167T3 (da) | Sammensætninger og fremgangsmåder til targeting af nucleinsyre med nucleinsyrer | |
| DK3578201T3 (da) | Fremgangsmåder og sammensætninger til naturlige dræberceller | |
| IL245573B (en) | Cell | |
| DK2970456T3 (da) | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer | |
| DK3363901T3 (da) | Sammensætninger og fremgangsmåder til præcis identificering af mutationer | |
| DK3080274T3 (da) | Fremgangsmåder og sammensætninger til genom-manipulation | |
| DK2884999T3 (da) | Fremgangsmåde og sammensætninger til cellulær immunterapi | |
| DK2981822T3 (da) | Sammensætninger og fremgangsmåder til vækstfaktormodulation | |
| DK2994533T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3685848T3 (da) | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension | |
| DK2830654T3 (da) | Metoder og sammensætninger til behandling af inflammation | |
| EP3011599C0 (en) | PHOTOVOLTAIC DEVICES | |
| DK2922955T3 (da) | Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression | |
| DK2970843T3 (da) | Fremgangsmåder til frembringelse af cellebank med høj densitet | |
| DK2552484T3 (da) | Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer | |
| DK3080302T3 (da) | Metoder og sonder til identifikation af genalleler | |
| DK3065790T3 (da) | Fremgangsmåder til fjernelse af alpha-galactose | |
| DK3013326T3 (da) | Skaldannende sammensætninger til bløde kapsler og bløde kapsler |